Top

Published in:

01-12-2010 | NON-THEMATIC REVIEW

Induction chemotherapy response and recurrence rates in correlation with N0 or N+ stage in oral squamous cell cancer (OSCC)

Authors: Lajos Olasz, Enikő Orsi, Tamás Markó, József Szalma

Published in: Cancer and Metastasis Reviews | Issue 4/2010

Abstract

The authors compared N0 with N+ cases in neoadjuvant chemotherapy regression and recurrence. During a 12-year period, 180 consecutive oral squamous cell cancer patients were observed. Of these patients, 78 were N0 and 102 N+ stages. The drugs used were as follows: bleomycin, vincristine, methotrexate, and mitolactol. After three courses of chemotherapy, the regression (complete response (CR), partial response (PR), and no response (NR)) and side effect rate were determined. All patients were operated on and observed for the number and localization of recurrences during 3 year follow-up time. The N0 cases came from T2–3, while N+ was from T2–4a (AJCC 2002). The regression in the N0 group was CR 46%, PR 53%, and NR 1%; but in the N+ group, it was CR 12%, PR 72%, and NR 16%. The regression rate was significantly higher (p = 0.00025) for N0 group than N+ group. The regression rate for T3 N0 was significantly higher (p = 0.055) than for T3 N+ cases. In the N0 stage, the regression rate was significantly higher (p = 0.0174) for T2 than T3. In N+ stage, there was no significant difference (p = 0.183) for T2–4a. The side effects were slight. The recurrence rate for the N0 group was significantly lower (15%, p = 0.000069), while for N+ group, it was 59%. The dependence in the T3 cases was also significant (p = 0.009) in the 3-year tumor-free survival. The N stage seems a more important prognostic factor for chemotherapy response and recurrence rate than the T stage. Stage III can be divided into subgroups without metastasis (III.a) and with metastasis (III.b.), based on significant difference in regression and recurrence rate.

Gaudi, I., & Kásler, M. (2002). The course of cancer mortality in Hungary between 1975–2001 (English abstract). Magyar Onkologia, 46, 291–295.PubMed

Németh, Zs, Velich, N., Bogdán, S., Ujpál, M., Szabó, G., & Suba, Z. S. (2005). The prognostic role of clinical, morphological and molecular markers in oral squamous cell tumors. Neoplasma, 52, 95–101.PubMed

Bettendorf, O., Piffko, J., & Bankfalvi, A. (2004). Prognostic and predictive factors in oral squamous cell cancer: Important tools for planning individual therapy? Oral Oncology, 40, 110–119.CrossRefPubMed

Taylor, S. G. (1997). Head and neck cancer. Cancer Chemother Biol Response Modif, 17, 428–443

Giralt, J. L., Gonzalez, J., Campo, J. M., Maldonado, J., Sanz, X., Pamias, J., et al. (2000). Preoperative induction chemotherapy followed by concurrent chemoradiotherapy in advanced carcinoma of the oral cavity and oropharynx. Cancer, 89, 939–945.CrossRefPubMed

Gibson, M. K., & Forastiere, A. A. (2004). Multidisciplinary approaches in the management of advanced head and necks: State of art. Current Opinion in Oncology, 16, 220–224.CrossRefPubMed

Forastiere, A. A., & Trotti, A. (1999). Radiotherapy and concurrent chemotherapy: A strategy that improves locoregional control and survival in oropharyngeal cancer. Journal of the National Cancer Institute, 91, 20056–22066.

Gibson, M. K., & Forastiere, A. A. (2006). Reassesment of the role of induction chemotherapy for head and neck cancer. The Lancet Oncology, 7, 565–574.CrossRefPubMed

Bryne, M., Koppang, H. S., Lilleng, R., & Kjaerheim, A. (1992). Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value. The Journal of Pathology, 166, 375–381.CrossRefPubMed

10.

Spiro, R. H., Guillamondegui, O., Paulin, A. F., & Huvos, A. G. (1999). Pattern of invasion and margin assessment in patients with oral tongue cancer. Head & Neck, 21, 408–413.CrossRef

11.

Psyrri, A., Kwong, M., DiStasio, S., Lekakis, L., Kassar, M., Sasaki, C., et al. (2004). Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: Long-term follow-up. Journal of Clinical Oncology, 22, 3061–3069.CrossRefPubMed

12.

Woolgar, J. A., Rogers, S. N., Lowe, D., Brown, J. S., & Vaughan, E. D. (2003). Cervical lymph node metastasis in oral cancer: The importance of even microscopic extracapsular spread. Oral Oncology, 39, 130–137.CrossRefPubMed

13.

Takes, R. P. (2004). Staging of the neck in patients with head and neck squamous cell cancer: Imaging techniques and biomarkers. Oral Oncology, 40, 656–667.CrossRefPubMed

14.

Basu, S., Khanra, M., Dash, B., Majumdar, J., Biswas, J., & Chaudhuri, P. (1999). The role of neoadjuvant and adjuvant chemotherapy regimens consisting of different combinations of drugs in the treatment of advanced oral cancer. Medical Oncology, 16, 199–203.CrossRefPubMed

15.

Benasso, M., Lionetto, R., Corvo, R., Ponzanelli, A., Vitale, V., & Rosso, R. (2003). Impact of the treating institution on the survival of patients with head and neck cancer treated with concomitant alternating chemotherapy and radiation. European Journal of Cancer, 39, 1895–1898.CrossRefPubMed

16.

Beckmann, G. K., Hoppe, F., Pfreundner, & Flentje, M. P. (2005). Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. Head & Neck, 27, 36–43.CrossRef

17.

Olasz, L., Szabó, I., & Horvath, A. (1988). A combined treatment for advanced oral cavity cancers. Cancer, 62, 1267–1274.CrossRefPubMed

18.

Olasz, L., Kwashie, F., Herczegh, P., Bruncsics, Z., Horváth, A., & Királyfalvi, L. (1996). A comparative study of preoperative B-V-M-M chemotherapy and irradiation in advanced squamous cell cancer of the oral cavity. Neoplasma, 43, 51–56.PubMed

19.

Woolgar, J. A., Rogers, S., West, C. R., Errington, R. D., Brown, J. S., & Vaughan, E. D. (1999). Survival and patterns of recurrence in 200 oral cancer patients treated by radical surgery and neck dissection. Oral Oncology, 35, 257–265.CrossRefPubMed

20.

Licitra, L., Grandi, C., Guzzo, M., Mariani, L., Lo Vullo, S., Valvo, F., et al. (2003). Primary chemotherapy in resectable oral cavity squamous cell cancer: A randomized controlled trial. Journal of Clinical Oncology, 21, 327–333.CrossRefPubMed

21.

Posner, M. R., Glisson, B., Frenette, G., Al-Sarraf, M., Colevas, A. D., Norris, C. M., et al. (2001). Multicenter phase I–II trial of docetaxel, cisplatin and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. Journal of Clinical Oncology, 19, 1096–1104.PubMed

22.

Sutton, D. N., Brown, J. S., Rogers, S. N., Vaughan, E. D., & Woolgar, J. A. (2003). The prognostic implications of the surgical margin in oral squamous cell carcinoma. International Journal of Oral and Maxillofacial Surgery, 32, 30–34.CrossRefPubMed

23.

Jacobs, J. R., Ahmad, K., Casiano, R., Schuller, D. E., Scott, C., Laramore, G. E., et al. (1993). Implications of positive surgical margins. The Laryngoscope, 103, 64–68.CrossRefPubMed

24.

Maipang, T., Maipang, M., Geater, A., Panjapiyakul, C., Watanaarepornchai, S., & Punperk, S. (1995). Combination chemotherapy as induction therapy for advanced resectable head and neck cancer. Journal of Surgical Oncology, 59, 80–85.CrossRefPubMed

25.

Rapidis, A. D., Trichas, M., Stavrinidis, E., Roupakia, A., Ioannidou, G., Kritselis, G., et al. (2006). Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: Final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a 4-year follow up. Oral Oncology, 42, 675–684.CrossRefPubMed

26.

Greene, F. L., & Page, D. L. (2002). AJCC cancer staging manual (6th ed., pp. 17–25). New York, NY: Springer.

Title: Induction chemotherapy response and recurrence rates in correlation with N0 or N+ stage in oral squamous cell cancer (OSCC)
Authors: Lajos Olasz
Enikő Orsi
Tamás Markó
József Szalma
Publication date: 01-12-2010
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 4/2010
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-010-9259-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

DNA methylation or histone modification status in metastasis and angiogenesis-related genes: a new hypothesis on usage of DNMT inhibitors and S-adenosylmethionine for genome stability

Regulatory T cells and breast cancer: implications for immunopathogenesis

Stem cell marker olfactomedin 4: critical appraisal of its characteristics and role in tumorigenesis

The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network

Expression of tenascin-C and its isoforms in the breast

Metastasis-related miRNAs, active players in breast cancer invasion, and metastasis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer